Media stories about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.3962701916795 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

BCLI has been the subject of several analyst reports. ValuEngine downgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. Maxim Group set a $9.00 price objective on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 16th.

Shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) opened at $3.19 on Monday. Brainstorm Cell Therapeutics has a 12-month low of $2.48 and a 12-month high of $5.18. The stock has a market cap of $60.11, a P/E ratio of -10.29 and a beta of 1.47.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the business posted ($0.09) earnings per share. equities analysts anticipate that Brainstorm Cell Therapeutics will post -0.37 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://theolympiareport.com/2017/12/25/brainstorm-cell-therapeutics-bcli-getting-somewhat-positive-media-coverage-report-finds.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Insider Buying and Selling by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.